Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
05 déc. 2023 12h26 HE
|
Syapse
Research collaboration between Syapse and the FDA Oncology Center of Excellence extended to assess fit-for-purpose RWD and explore the potential of RWE.
Custom Research Presented at AMIA Informatics Summit Reveals Promising Findings for Healthcare Innovation
14 mars 2023 08h05 HE
|
Syapse
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
Syapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand Cancers
15 sept. 2022 08h00 HE
|
Syapse
SAN FRANCISCO and NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
Syapse and Genesis Research Combine Forces to Offer Real-World Evidence Services and Data to Oncology Innovators
31 août 2022 08h00 HE
|
Syapse
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
27 juil. 2022 09h00 HE
|
Syapse
SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
14 juin 2022 10h00 HE
|
Syapse
SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...
Syapse Unveils Two New Studies on Use of Machine Learning on Real-World Data to Identify and Treat Cancer With Precision at ASCO 2022
27 mai 2022 10h00 HE
|
Syapse
SAN FRANCISCO, May 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...
Syapse Announces Changes to Board of Directors, Adding Michael Mentesana and Elevating Frank Williams to Chairman Role
31 mars 2022 10h00 HE
|
Syapse
SAN FRANCISCO, March 31, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
Main Line Health Collaborates with Syapse, Bringing Clinical Trial Opportunities to Patients with Cancer in Philadelphia Region
22 mars 2022 10h00 HE
|
Syapse
SAN FRANCISCO, March 22, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
Syapse Extends Collaboration with Pfizer to Continue to Generate Real-World Evidence in Breast Cancer
20 janv. 2022 10h00 HE
|
Syapse
SAN FRANCISCO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today...